larg cap sector weight market weight
competit grower good valuat alreadi reflect
eylea growth solid biosimilar confer major singl product
concentr risk invit comparison
dupix share w/sanofi great drug competit threat repres
asymmetr risk downsid consensu larg dismiss
report limit sole use client wolf research pleas refer disclosur section locat end report analyst certif
disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc lexington avenu suit new york ny
tabl content
regeneron initi peer perform rate
summari view window good growth declin begin current valuat suggest
fairli valu dupix great even enough sustain lt growth
initi peer perform rate blue chip biotech simplist live die
perform two product eylea dupix make vast major current futur revenu
eylea great heavi singl product concentr risk total revenu today leav
w/highest singl product concentr risk name cover grow nice us biosimilar
dupix second import product clean effect quit possibl reach eur peak
sale san guid howev
even peak would current consensu enough drive posit
compel growth partli bc econom split w/san
near-term competit threat repres asymmetr risk downsid
consensu larg dismiss atop derm asthma
dupi threat head-to-head jak trial atop derm pfe jade compar top-lin
abbv head also asthma data novel moa tezepelumab azn/amgn
 regn core capabl solid current late-stag pipelin doesnt quit enough
oomph excit go roch area
variou reason like domin
price target current price
reli price-to-earnings multipl ep vs peer group averag rang
impli price-to-earnings multipl ep vs peer group averag rang
dcf analysi inform basi price target calcul cover name
yield valu
ltm boost eas fear medicar part reform strong dupix
ytd boost eylea competitor beovu setback also partial covid play
feb trump comment
beovu analyst upgrad
feb hh
collab covid mab
trial updat mab
new safeti concern novarti beovu boost
regard vascul beovu like make nearli doa
allow eylea continu grow loe
way lever singl product rel
short runway left share distinct similar
heavi depend product start see
biosimilar competit within year
might eylea biosimilar take longer get approv
expect although biosimilar manufactur current
guid launch develop product
difficult ascertain similar
dupix estim low analyst estim still
san guidanc eur peak
indic expans area like copd food allergi
could drive sale even higher next humira
proven track record late-stag asset
proven get sever product across
regulatori finish line current late-stag pipelin
continu sourc upsid
libtayo investor expect modest strong lung
data right price strategi sale could beat
potenti takeout would bring acquir biologically-
focus engin opportun substanti cost
dupix realli get eur given competit
compar abbv head plu potenti new
competit asthma azn/amgn tezepelumab san
long-term revenu ep growth beyond
rel anem even big dupix estim
follow eylea loe growth profil enter
prolong period mediocr downsid
biosimilar becom interchang point erod
faster street model
earn rel mani big biopharma
compani continu exclud stock option
base compens non-gaap ep
san elect sell stake would put
slow pressur price even though limit share
everi could continu year compani
choos liquid follow expir lock-up period
high depend singl product sound familiar
regeneron heavi relianc eylea abbvie-lik problem term singl
note similar shape co revenu driven similar window
biosimilar risk humira eylea
despit similar regn price-to-earnings multipl abbv
total revenu mix
eylea total rev
humira total rev
earli pipelin standard calcul use model assum certain rate return
 spend yield futur pipelin product specif cant known today
catalyst bigger one
b-cell malign
pozelimab inhibitor complement-medi diseas
dupix indic expans new drug per se
sanofi decis sell stake
competitor event tezepelumab asthma data amgn/azn
competitor event lebrikizumab atop derm data
competitor event upadacitnib vs dupix ad
pipelin snapshot time news what model
assettarget wr estimatesnext like import updat result fih studi potenti file fda file hofh top-line hypertriglyceridemia/pancreat top-line hypercholesterolemia long-term efficaci safeti data top-line monotherapi data ad top-line data /- dupix ad interim data afibrodysplasia ossifican potenti fda file phase ii data updat fih data dose escal base revenu vs peer big biotech pharma
base revenu analysi look product market today
 assum futur pipelin drug fail measur durabl
among best posit period
middl pack period
outlook index
outlook index
unlik prior slide show total revenu ie base pipelin assumpt
well-posit among peer time-frame
ep growth middle-of-the-pack contract eylea loe
outlook index
outlook index
sanofi enter broad collabor develop fulli
antibodi collabor dupix praluent kevzara limit pipelin
basic split structur joint develop commerci
agreement san book sale pay profit split well
reimburs certain commerci cost
announc restructur take praluent us san take
praluent ex-u also get kevzara ww chang dupix
royalti flow still parti asset close
addit san own share outstand collect proport
total compani profit equiti method account
analyst meet san say may seek monet stake
lock-up period expir
biosimilar eylea mark inflect
product revenu hyperlipidemia antibodi earli phase total profit profit incom growth select approv product overview see later slide
eylea retin diseas construct eylea growth prospect
especi follow asrss warn novarti beovu heavili impair brand assum
statu quo market eylea lead lucenti off-label avastin take slack minim
disrupt competitor pipelin drug like rog faricimab data model assum us biosimilar
eu uncertainti exact time biosimilar entri well rate uptak
dupix inflammatori condit crown jewel san-regn collabor
expect consist growth decad label expand least new indic eoe prurigo
nodulari etc forecast call peak sale honor sanofi guidanc
assum competit jak inhibitor novel biolog dont threaten dupix primaci atop
dermat asthma howev competit threat harder assess azn/amgn tezepelumab data
wait see competitor threat therefor repres sourc downsid
consensu larg appear dismiss one sourc major upsid would posit result borea
trial copd pcd note howev biolog yet shown work copd slide
libtayo cancer libtayo unenvi posit sixth market highli
competit space current domin main market leader azn set sight
nsclc acceler growth outsid cscc studi difficult us see make
meaning inroad could disrupt price late-entr histori shown sustain
differenti competitor match price leav payer winner slide
praluent cholesterol regn inhibitor like continu lag amgn repatha
despit optic better cvot data all-caus mortal benefit trail time outcom data
uncertain whether without sanofi commerci muscl us compet effect
cancer earli data follicular lymphoma encourag direct better
respons rate vs soc multiple-relaps fl although earli data appear lag roch data also support class
drug viabl clear activ perhap biggest question expect compet roch
two asset space consid rog commerci know-how infrastructur oncolog
none slide
evinacumab cv diseas despit impress data hofh struggl see signific commerci
opportun evinacumab hofh ultra-orphan diseas yet may abl price quit orphan level
partli compet low-cost inhibitor target larger indic like sever hypertriglyceridemia
phase ii could requir cvot util slide
pozelimab pnh estim model start soon earli data posit ldh lower look
optic better soliris/ultomiri think difficult drive pnh patient switch pozelimab especi
continu success switch patient second-gener ultomiri outsid pnh lag far
condit except chapl complement hyperactiv angiopath thrombosi protein lose
enteropathi potenti differenti cemdisiran sirna combo without clinic
data soon ascrib valu slide
garetosmab fop estim model follow mix data studi garetosmab miss
primari endpoint total lesion activ possibl due small lesion volum work fda figur
next step potenti file even success regulatori perspect commerci proposit
fibrodysplasia ossifican progressiva limit given patient world-wide slide
fasinumab pain estim model ngf class plagu concern rapidli progress osteoarthr
rpoa osteonecrosi lead clinic hold discontinu high dose formul fasinumab differ
view base disappoint data last year pfe/lli tanezumab mute expect ahead lt safeti
efficaci data even regn/teva eke regulatori win fasinumab still unlik gain meaning commerci
traction given experi class also fact pfe/lli still ahead queue slide
revenu ep estim vs consensu
ahead consensu revenu ep
howev difficult know true consensu estim vari wide
biggest sourc variat eylea estim whether theyr updat
beovu news san collabor revenu big semi-opaqu line item
beyond hard know analyst model dont go far go
comp sheet cover compani biotech pharma
excl upjohn azn w/o us/eu europ pharmaeu target multipl price-to-earnings growth analysi
look appropri posit vs peer near medium-term
use rel valuat methodolog determin price target use target price-to-earnings
multipl appli forward ep
target multipl primarili take account pipelin option binari event risk near- long-term
pt repres target multipl ep current
trade ep
rang target multipl use cover compani span
also show dcf calcul use determin pt
per share dcf valu equitynpv cash flow termin valu per stock tgr wacc eylea
talk singl product concentr risk
fortun good growth next year
beovu bite dust
eylea growth continu next year healthi clip partli aid novarti major
recent feb setback beovu
assum product face direct biosimilar indirect pressur
lucenti biosimilar perhap year ahead incorpor pediatr extens
assum major market disrupt either form new competit
current dont give credit regn earli follow-on product eylea
window
growth close
year
regn singl largest product anti-vegf fusion protein variou retin
us approv loe us like pediatr exclus
full us ownership bayer market ex-u split net profit w/
forecast peak sale year biosimilar vs sale
competitor rank import lucenti novartis/roch avastin roch off-label
competitor product novarti beovu
like major way
indirect pressur biosimilar
competitor still come market
 rog faricimab
gene therapi could remov need
repeat inject existenti threat
eylea recent news novarti beovu
oct novarti receiv fda approv beovu new therapi
better dri back eye label
buton feb becom public american societi retin surgeon
asr issu safeti warn member say beuvo may lead inflamm
possibl blind
novarti hire outsid expert assess analysi on-going late probabl
next day see stock increas nearli
clearli competitor like good ever destin
eylea killer anyway
despit nv management prior bullish nv analyst sale
beovu label differenti
expect also temper biosimilar lucenti eylea come
year
eylea beovu bite dust competit monitor
rog data underwhelm regn nevascumab didnt look
great combin eylea
ph wet dme top-line
present seem unlik take materi share
show high intraocular inflamm rate cedar sequoia lucenti
activ compar
fda decis
present seem unlik take share may even dead
chines eylea mean structur mechanist similar
chengdu undercut price take share mayb china
countri tbd
phase panda data late eylea
present enough data know whether real risk
high molecular weight confer superior pk profil abl dose
infrequ
phase data namd rvo late eylea broad retin bla
bit close eylea
eylea indirect pressur biosimilar lucenti
biosimilar lucenti time best guess us
creat indirect price pressur remain brand
medicar advantag advent step-therapi payer forc
use lower-pr biosimilar step therapi could impact eylea price
volum
base lower asp maintain econom part reimburs
biosimilar asp lucenti asp especi biosim manufactur will
match rebat eylea brand lucenti
commerci plan increas number low-cost altern give
commerci payer increas leverag push price brand
eylea composit matter com patent expir us eu
pediatr studi would push us biosimilar model
bayer on-going trial retinopathi prematur
butterfley ped extens
sever eylea biosimilar develop would expect tabl
could hurdl approv biosimilar medicin given intra-
ocularli given difficulti measur tradit pk/pd data tbd
moleculecompanyphasenext iiitoplin data iiitoplin data itoplin data file eylea gene therapi risk partli depend time
gene therapi work could repres existenti threat would
howev viabil program still tbd select program tabl
equal import time gene therapi make market
may come around time eylea patent expiri
would still impact eylea biosimilar doesnt fall
cliff right away
biomedicaiendostatin angiostatin eylea could impact propos medicar part reform
eylea competitor drug lucenti two largest spend line item
medicar part total chart
eylea singl largest drug expenditur part
eylea sale channel part account
price lower price countri part reform could materi impact eylea
belief remain see light day
like part eventu reform less impact way
great product next humira
dupix fare competitor
pipelin product atop derm asthma
new indic work
atop dermat ad dupix continu grow despit competit launch given
product profil broaden age-rang market under-penetr
similarli asthma assum major paradigm shift compet product
take san guidanc peak sale eur face valu seem reason
given current trajectori futur indic expans
upsid option posit borea data copd includ estim
biolog asthma yet work set
receptor alpha antagonist block pathway work
approv atop dermat ad asthma nasal polyp crswnp
first approv us loe assum patent term restor grant
forecast sale vs sale san guid peak
crown jewel regn antibodi collabor san slide split
first mover biolog atop
derm nasal polyp approv
biolog competitor moment
ad moa near read-out
and/or launch jak closest
lly/dermira
atop
asthma crowd exist
competitor
market even late-stag develop
competit new moa
xolair biosimilar relev
asthma indic dupix
dupix develop program catalyst timelin
broad develop program dupix across atop condit age rang
provid number opportun expand commerci opportun
includ combo act upstream dupix
howev data class mix thu far
data slate come howev make quieter year
dupi dupi yearsiiiborea dupi monotherapi atop yearsiiiliberty-ad-preschool dupi yearsiiivoyag dupi ad current control atop dupi combo peanut monotherapi prurigo yearsiiiprim dupi soc chronic spontan yearsiiicupid dupi dupix indic atop dermat
dupix achiev statist signific across primari secondari
endpoint trial
rapid resolut itch drive improv outcom arrest itch-scratch
patient develop conjunct risk benefit still favor given pauciti
effect therapi sever ad major resolv eye drop
dupix low score leav room improv
question worth ask time could atop dermat space develop
similar psoriasi pso space
recal histori later-entr pso therapi deliv stringent respons
respons rate rang dupix theoret
seem possibl data competitor ad yet show
trial
dupix head-to-
near-term
compar lt use toplinejad regimen toplinejad teen toplinephas toplineepion toplinead combo studi toplinehead top-line dupix jak inhibitor ad real riskor headfak
current run late-stag trial jak inhibitor ad
jak efficaci attribut may includ strong score chart fast
onset less itch dupix demonstr jade compar
jak liabil thromboembol event black box class label
dupix safeti find jak may tri exploit conjunct blood eosinophilia
howev jak also offer obviou differenti oral
dupix vs jak easi
side-by-sid comparison differ trial
dupix jade compar deliv need safeti detail
march announc top-line data jade compar trial
efficaci similar lesion clearanc dupi stat sig better itch relief week
mg dose trend lower dose
safeti rate dissimilar pbo dupi need detail specif
reason discontinu
question ponder high dose abro even get approv fda previous
deni high dose jak indic
dupix apart oral jak mani biolog competitor watch
mid- late-stag pipelin full cytokine-target antibodi like
dupix although none specif
go ad other go asthma minor go
risk dupix enough data say
productmanufacturerphasemechan antibodytralokinumableo antagonisttezepelumabamgeniibtslp antibodybi modul dupix lli lebrikizumab could offer dose advantag ad
lly/dermirass lebrikizumab demonstr compar
dupix vs dupix
howev side-by-sid comparison lebri vs dupi trial
lebrikizumab trial read mid- to-lat head-to-head vs dupix
dupix receiv approv asthma age
oct fda approv eosinophil asthma oral corticosteroid oc
depend asthma regardless phenotyp
may ema approv eosinophil asthma
launch well indic
first biolog home administr although other offer
biolog approv ocs-depend patient regardless
better commerci organ vs competit area per industri contact
help market access patient journey
also run trial addit subgroup
liberti asthma excurs children asthma
also studi copd describ detail slide
eosinophil asthma bigger two opportun compet sever
biolog xolair nucala gsk fasenra azn cinqair teva
ocs-depend asthma regardless eo dupix differenti among
newer biolog label restrict eo phenotyp
howev older biolog xolair technic limit eo phenotyp either
approv
dupix vs nucala reduc need oc
side-by-sid comparison dupix outperform nucala stringent
endpoint ocs-fre high reduct threshold may confound
patient ventur lower sever asthma exacerb slightli higher acq-
score materi higher blood eosinophil count rel siriu despit
all-com
degre steroid reduct
june dupix approv chronic rhinosinus nasal
polyp crswnp adult basi
sinu placebo-control trial compar dupix
placebo anatom symptomat score
sinu studi includ dupix dose arm
initi week
exact mechan polyposi fulli understood thought
relat cytokin given high coincid rate asthma
design sinu trial focu patient remain symptomat
follow surgic resolut system steroid use
patient endoscop surgeri see polyp recurr
dont view crswnp signific new stand-alone commerci
opportun fair amount overlap asthmat
dupix next deck eosinophil esophag
dupix phase trial eosinophil esophag eoe base posit
trial enrol patient exclud patient comorbid gi condit
first read-out part inform part registr design
eoe preval claim patient us although
addit atop cormibid per case studi may alreadi part
hand therapi moa
pipelin go eoe earlier stage
dupix may therefor first mover advantag set
oral could carri day conveni tak budesonid
solut exactli high scienc
failur eoe worth rememb nucala cinqair reduc
esophag eosinophil symptom improv
dupix next deck copd like long shot
dupix phase borea trial chronic obstruct pulmonari diseas copd
base asthma mechanist studi direct poc data copd
read
borea enrol patient moderate-to-sever dieas
patient must eosinophil copd incorpor find prior fail
studi see slide eosinophilic-agnost copd
copd holi grail sort result close odd seem low
manag seem strike cautiou tone probabl success
import histori thu far biolog asthma drug work copd
xolair copd trial stall ago develop
gsk nucala file approv mix data shot fda panel mid
azn fasenra two fail trial subset analysi compel start
new trial call resolut read late
azn/amgn tezepelumab current copd read earli
dupix next deck food allergi
dupix phase studi peanut allergi monotherapi well
adjunct oral immunotherapi
hard handicap odd success
xolair previous shown efficaci signal formal studi
broader food allergi indic read mono adjunct
trial also hit show prior efficaci signal program
advanc
smaller trial pediatr
partner aimmun use dupix
singl arm trial control
start read
efficaci week
like larger opportun adjunct
use given would like requir
chronic dose prevent symptomat
reaction exposur
adjunct palforzia peanut
protein similar tradit
trial pediatr
start read
efficaci week
would episod like translat
next-gen dupi much
regn inhibitor current develop rang
act upstream inflammatori cascad primarili drive
mix result thu far benefit broader spectrum activ translat
improv efficaci pan yet
asthma trial evalu monotherapi combin dupi
monotherapi better dupi control arm
combo w/dupi better dupi control arm
despit discourag data continu investig
atop dermat asthma hope find subgroup amen
compet major pdx
expect nsclc mono ahead
could second gen i/o reset field give
libtayo commerci success larg limit nich indic competit less
even studi nsclc hit see libtayo garner signific share
competitor i/o combo like advanc ahead libtayo combin effort
prevent gain lead posit
mrk keytruda data cscc compar libtayo cut
libtayo market
libtayo cemiplimab regn inhibitor cutan squamou cell carcinoma
cscc infrequ skin cancer cornerston regn/san io effort
approv us sept us loe us indirect pressur biosimilar
keytruda/opdivo
forecast us sale vs sale
market libtayo us san market ex-u develop split
studi on-going broaden approv use
first mover advantag dermato-
late entrant bigger indic
oncolog indic cscc
temper success new indic
could call option upsid
still white space adjuv set
combo gen io agent
exactli oncolog
powerhous san partner help
like undifferenti mab
given target like similar
dissimilar gener rule
limit combo program underway
intern extern seem
libtayo trail rest pdx packbig time
pdx ww sale launch
libtayo develop program help transform
libtayo develop program includ number higher-valu indic
like nsclc competit fierc
import question late entrant libtayo compete/differenti
clinic profil superior like also thu far
similar unexpect
compet price rare win strategi competitor match
like libtayo opportun mostli niche-i indic like cscc major
indic probabl get crumb
nsclc monotherapyapprovedxin trialsin trialsin nsclc chemo comboapprovedin trialsin trialsin trialsin neoadjuv nsclc hnsccin trialsin trialsin cervic cancerin trialsxxxin pediatr gliomaxxxxx libtayo nsclc trial optim succeed
trial enrol patient
expand enrol roughli size keynote-
slightli larger cohort
importantli exclud never smoker group made keynote-
never smoker subgroup hr benefit
exclud subgroup result could look better side-by-
side comparison alreadi kind show interim-look see next slide
final result stronger matter commerci nah
also screen exclud fusion lung tumor
screen
libtayo interim look mono look like first blush
novemb announc interim efficaci data
orr data look similar keytruda term absolut benefit
numer superior slight placebo-adust basi
give rise bull case final os data may optic look better keytruda
respons rate vs trial
libtayo whole lot go io combin
although optimist abil level play field
combo late-entr statu lack critic mass may struggl
prefer partner would market leader like mrk keytruda bmi
opdivo fact hundr combo trial alreadi run establish
product chart
unlik small biotech compani look partner libtayo despit
combo trial
praluent stack repatha
long-term could novarti new
inclisiran mdco overtak market
introduct low cost praluent ndc price cut help drive increment volum
praluent like remain unabl overcom repatha first-mov advantag
unclear novn inclisiran launch hinder praluent growth near-term
remain product smaller import
praluent regn inhibitor lipid manag
approv loe
forecast us sale vs sale
recent reclaim us right dont expect much chang
praluent odyssey outcom data
better repatha fourier
odyssey data came far behind
fourier drive inflect
overhang continu litig
product remov germani
futur competit disrupt
go alon
uslos san market muscl
dtc far vs amgn frequent
praluent amgn repatha current market leader
repatha praluent compar term market share earli
announc top-line data fourier make first show
outcom benefit
amgn first-to-have-outcomes-data advantag remain durabl even
though praluent claim overal mortal benefit
inclisiran asset behind novarti acquisit mdco
sirna product extend dose
ldl-c lower appear modestli weaker side-by-sid comparison
better efficaci valu proposit
rather valu proposit dose vs praluent/repatha
howev inclisiran uptak like slow novn data
doesnt come
question could novarti disrupt w/inclisiran price near-term
excit new class drug
stack
ever realli beat
bispecif antibodi clinic trial blood cancer
facili connect t-cell malign b-cell bind t-cell co-
receptor b-cell antigen
main competitor roch two asset mosunetuzumab
event potenti registr data
model vs consensu risk-adjust
feel ahead pivot data readout
could first cross finish line follicular lymphoma data
right respons depth appear modest vs polivi car-t
shelf dose bispecif signific commerci advantag doc
vs car-t conveni reimburs perspect medicar part vs
part major car-t patient
question bind domain remain air igm develop
respect bispecif
would need significantli better data outmaneuv backyard
even first mover advantag
fl patient dose mg cr orr mdor reach
compar rituxan/revlimid orr cr gazyva/bendamustin
orr cr less heavili pretreat patient
patient prior car-t dose cr orr
fl dlbcl higher dose activ
relapsed/refractori b-cell non-hodgkin lymphoma present
seem like approv dlbcl therapi
earli data suggest broadli similar vs car-t novn
safeti neurotox look similar
earli data suggest also broadli similar vs polivi
celgen rocheregeneroncostimulatori follow-up dor releas better
rog compet product mosunetuzumab appear compar
lot caveat side-by-sid analysi earli data compound
high may durabl
less mosunetuzumab
drug dose-escal meaning comparison possibl
expans cohort yet avail
schuster mosunetuzumab indicu complet remiss poor prognosi
non-hodgkin lymphoma patient includ resist relaps
chimer antigen receptor t-cell car-t therapi activ treatment
multipl line present
therapymosunetuzumab dlbcl mosunetuzumab inhl manufacturerrocheregeneroncostimulatori follow-up dor month nrnrnrcost releas roch second shot goal better mouse-trap
other like design bi-specif mab multipl
goal increas affin b-cell therefor
abl compet therapeut washout abl combin soc
may overcom partial loss express rituxan-refractori patient
could lead lower cytokin releas claim igm fih expect
igm op cover wr akash tewari
rog design allow regimen differenti
monotherapi appear broadli similar high dose
cr orr mdor reach
abil combin soc gazyva could mean higher
load bolu gazyva debulk peripher b-cell lead lower rate
therapeut gazyva combin boost cr rate highest dose
cant combin soc
ever outmaneuv nhl hmmm
rog current portfolio asset abil entir
continuum care indol aggress form nhl
leverag portfolio explor multipl combin across treatment
set optim safeti efficaci commerci impact
mosunetuzumab consolid follow dlbcl
mosunetuzumab chop mosunetuzumab polivi chp novel
mosunetuzumab polivi bendamustin later
oh yeah dont forget sell blood cancer biolog sinc
late rituxan approv
sum unless abl gener significantli better data impact
may rippl wave
regn monotherapi program diseas specif cohort could push across
finish line first matter combo-domin space like hem-onc
run combo shown
consolid dlbcl
polivi combo nhl
libtayo combo lymphoma
death far
tecentriq combo nhl cll
revlimid combo r/r fl
chop combo nhl
polivi chp combo nhl
what hurdl pozelimab beat alxn
pozelimab address unmet need
pozelimab regn inhibitor current phase ii trial treatment
partner run combin trial cemdisiran sirna therapeut
event interim potenti pivot phase ii data
model model
feel ahead interim data
patient initi dataset reach uln ldh compar patient
soliri ultomiri albeit small dataseta would like expect
lower respons rate phase ii studi
data appear direct better alxn product note pozelimab
unlik affect major sourc treatment failur like hemolysi
question whether abl success convinc pnh patient switch
switch away trust incumb
could find novel way improv efficaci like cemdisiran combo
earli ascrib valu
pozelimab soliri set hurdl pnh
alxn soliri effect hemoglobin stabil reduc hemolysi base
ldh level set bar regn pozelimab therapi
roughli half soliri patient achiev normal ldh level
despit clinic signific ldh data less third patient achiev
alxn follow-on ultomiri hardli step-wis improv soliri efficaci
rather major benefit dose frequenc mayb eventu
conveni potenti sc dose
decemb announc posit data first pnh patient
treat pozelimab
patient achiev normal ldh level week pozelimab versu
soliri ultomiri side side comparison
patient reach uln ldh week rapid onset
underli bone marrow dysfunct
regn choic epitop support trial enrol one patient
known variant typic resist complement inhibitor
preval variant low
enrol second phase trial compani believ could
support bla file interim data
fasinumab nerv growth factor ngf inhibitor late-stag develop
manag chronic pain develop teva
ngf regul function sensori sympathet neuron modul
event long-term safeti efficaci data oa pain
model carri forecast model vs consensu
feel ahead phase data
ngf class rocki develop histori efficaci lag opioid
seriou name rpoa osteonecrosi
tanezumab data like canari coal mine fasinumab
fda concern around fasinumab high dose reinforc idea fasinumab
safeti profil differenti rest class
opioid crisi creat attract backdrop novel pain manag
mechan paradigm oa shift diseas modif
overal even regn/teva win approv fasinumab unlik
regn wholly-own antibodi lipid manag begin rare
inhibit lipoprotein endotheli lipas key regul triglycerid
phospholipid hydrolysi play key role lipoprotein metabol
report posit phase data august hofh on-going phase
ii trial hypertriglyceridemia hypercholesterolemia
event file hofh data indic
model vs consensu
feel ahead launch indic expans
hofh like limit commerci opportun given low patient count
current ascrib valu earlier phase ii indic pre-poc
acknowledg role pathway
pursu larger indic like persist hypercholesterolemia
may requir cvot becom commerci viabl
overal dont think evinacumab move needl materi hofh
alon could chang indic expans
regn anti-activin antibodi treatment fibrodysplasia ossifican
progress sibm trial withdrawn
activin belong class protein crucial fetal develop also
report phase ii data garetosmab narrowli miss statist
signific primari endpoint think may still approv
model carri forecast model vs consensu
feel ahead garetosmab file
narrowli miss primari endpoint total lesion activ
encourag data new lesion activ reduct pair unmet need
commerci howev fop unlik signific contributor revenu
preval
overal harder handicap fda action materi stori
incom statement oper incom expens outstand margin total profit profit profit incom growth oper balanc sheet flow
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang debt/leas exercis stock option treasuri flow financ activ fx cash increas decreas cash sheet cash equival st properti plant tax current leas non-curr comprhens sharehold liabil sharehold disclosur section analyst certif analyst wolf research llc primarili respons research report whose name appear first front page research report herebi certifi recommend opinion express research report accur reflect research analyst person view subject secur issuer ii part research analyst compens directli indirectli relat specif recommend view contain report import disclosur price chart rate price histori note op outperform pp peer perform under-perform wolf research llc fundament valuat methodolog compani fundament valuat methodolog price-to-earnings target multipl forward ep estim wolf research llc fundament recommend rate price risk compani risk may imped achiev recommend rate price upsid risk pt big win lung libtayo boost revenu win dupix borea trial copd pipelin capabl cant write earli pipelin asset becom next big thing downsid risk pt emerg competitor eylea gener favor profil dupix fail new indic novel competit threaten atop dermat asthma big pdx player truda opdivo etc enter libtayo nich regeneron fail find heir eylea ahead exclus wolf research llc research disclosur compani research disclosur none disclosur wolf research llc fundament stock rate outperform op secur project outperform analyst industri coverag univers next month peer perform pp secur project perform approxim line analyst industri coverag univers next month under-perform secur project under-perform analyst industri coverag univers next month wolf research llc use rel rate system use term outperform peer perform under-perform see definit pleas care read definit rate use wolf research llc research addit sinc wolf research llc research contain complet inform concern analyst view pleas care read wolf research llc research entireti infer content rate alon case rate research use reli upon invest advic invest decis base upon individu circumst consider wolf research llc sector weight market overweight mo expect industri outperform primari market index region least next month market weight mw expect industri perform approxim line primari market index region next month market underweight mu expect industri under-perform primari market index region least next month wolf research llc distribut fundament stock rate march outperform invest bank client peer perform invest bank client under-perform invest bank client wolf research llc assign rate buy hold sell stock cover outperform peer perform under-perform respect equival buy hold sell repres rel weight defin satisfi regulatori requir outperform design correspond buy peer perform design correspond hold under-perform design correspond sell wolf research secur wolf research llc adopt use wolf research brand name wolf research secur member finra www finra org broker-deal affili wolf research llc respons content materi analyst publish report dualli employ wolf research llc wolf research secur content report use sole inform purpos regard offer solicit offer buy sell secur financi instrument servic discuss herein opinion commun constitut current judgment author date time report subject chang without notic inform herein believ reliabl wolf research affili includ limit wolf research secur make represent complet accur inform provid commun design replac recipi decision-mak process assess propos transact invest involv financi instrument discuss herein recipi encourag seek financi advic financi advisor regard appropri invest secur financi instrument refer report understand statement regard futur perform financi instrument secur referenc herein may realiz past perform indic futur result report intend distribut use person entiti locat distribut use would contrari applic law would subject wolf research llc affili registr requir within locat addit import disclosur pleas see www wolferesearch com/disclosur view express wolf research llc research report regard sector and/or specif compani may time time inconsist view impli inclus sector compani wolf research llc analyst research report model screen wolf research commun client across varieti medium client choos includ email voic blast electron public proprietari websit copyright wolf research llc right reserv materi present document unless specif indic otherwis copyright wolf research llc none materi content copi may alter way transmit distribut parti without prior express written permiss wolf research llc report limit sole use client wolf research author user receiv encrypt decod legisl monitor access wolf research llc content
